Compare ResMed Inc. (RMD) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Visa Inc — how do they compare? ResMed Inc. trades at $227.51 (market cap $31.78B), while Visa Inc trades at $374.9 (market cap $698.56B). The key difference: Visa Inc is far larger — about 22× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Visa Inc for 115 Days on average.
| RMD | V | |
|---|---|---|
Market Cap | $31.78B | $698.56B |
Volume | 1,128,382 | 4,446,146 |
Sector | Health | Financials |
52-Week High | $277.88 | $384.14 |
52-Week Low | $182.82 | $295.52 |
Typical Hold Time | 51 Days | 115 Days |
Enterprise Value | $31.14B | $709.14B |
Dividend Yield | 1.17% | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Visa (V) trades at $375.10, up 1.2% today, with a bullish technical outlook and strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $40 billion and net income of $20.06 billion, supported by high profitability margins. Recent earnings beats and a consensus analyst price target of $422.24 reflect positive sentiment, while news highlights AI integration and stablecoin partnerships as growth catalysts.
The outlook for Visa remains favorable, driven by earnings momentum and strategic initiatives in digital payments. Key risks include competitive pressures from fintech and regulatory scrutiny, but institutional ownership trends and a dominant market position underpin long-term potential. The stock offers upside based on analyst targets, though investors should monitor execution on AI and payment innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
